Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection

Journal of Viral Hepatitis

Volumn 18, Issue 2, 2011, Pages 129-134

  Rosenberg, P ^a,b   Hagen, K ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

B12; hepatitis C; infection; interferon; ribavirin; treatment

Indexed keywords

ALPHA2B INTERFERON; CYANOCOBALAMIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SERUM; TREATMENT RESPONSE; VIRUS HEPATITIS; VITAMIN BLOOD LEVEL;

EID: 78751541952     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01288.x     Document Type: Article

References (22)

1. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5 (9): 558-567.
2. Seeff LB, Hoofnagle JH,. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 5 (Suppl. 1): S1-S2.
3. Ascione A, Tartaglione T, Di Costanzo GG,. Natural history of chronic hepatitis C virus infection. Dig Liver Dis 2007; 39 (Suppl. 1): S4-S7.
4. Strauss R, Torner A, Duberg AS, Hultcrantz R, Ekdahl K,. Hepatocellular carcinoma and other primary liver cancers in hepatitis C patients in Sweden-a low endemic country. J Viral Hepat 2008; 15 (7): 531-537.
5. Amin J, Dore GJ, O'Connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol 2006; 45 (2): 197-203.
6. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP,. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45 (4): 529-538.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
8. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40 (6): 993-999.
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
11. Reynolds E,. Vitamin B12, folic acid, and the nervous system. Lancet Neurol 2006; 5 (11): 949-960.
12. Toh BH, van Driel IR, Gleeson PA,. Pernicious anemia. N Engl J Med 1997; 337 (20): 1441-1448.
13. Li D, Lott WB, Martyn J, Haqshenas G, Gowans EJ,. Differential effects on the hepatitis C virus (HCV) internal ribosome entry site by vitamin B12 and the HCV core protein. J Virol 2004; 78 (21): 12075-12081.
14. Takyar SS, Gowans EJ, Lott WB,. Vitamin B12 stalls the 80 S ribosomal complex on the hepatitis C internal ribosome entry site. J Mol Biol 2002; 319 (1): 1-8.
15. Lott WB, Takyar SS, Tuppen J, et al. Vitamin B12 and hepatitis C: molecular biology and human pathology. Proc Natl Acad Sci USA 2001; 98 (9): 4916-4921.
16. Ermens AA, Vlasveld LT, Lindemans J,. Significance of elevated cobalamin (vitamin B12) levels in blood. Clin Biochem 2003; 36 (8): 585-590.
17. Baker H, Leevy CB, DeAngelis B, Frank O, Baker ER,. Cobalamin (vitamin B12) and holotranscobalamin changes in plasma and liver tissue in alcoholics with liver disease. J Am Coll Nutr 1998; 17 (3): 235-238.
18. Batts KP, Ludwig J,. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19 (12): 1409-1417.
19. Hadziyannis SJ,. Prognostic factors determining the outcome of treatment in chronic hepatitis C. Acta Gastroenterol Belg 2000; 63 (2): 207-209.
20. Saunier B, Triyatni M, Ulianich L, Maruvada P, Yen P, Kohn LD,. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol 2003; 77 (1): 546-559.
21. Seetharam B, Yammani RR,. Cobalamin transport proteins and their cell-surface receptors. Expert Rev Mol Med 2003; 5 (18): 1-18.
22. Borgia G, Gentile I, Fortunato G, et al. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver Int 2009; 29 (2): 248-252.